Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)

US · US National Institutes of Health (NIH) grant open #PAR-25-374

Response due May 07, 2028 · 00:00 UTC

Summary

The National Institutes of Health (NIH) is soliciting R01 research grant applications focused on translational bioinformatics and experimental approaches to advance drug repositioning and combination therapy development for Alzheimer's Disease and Related Dementias (ADRD). Clinical trials are explicitly excluded from this funding opportunity. The program aims to leverage computational and experimental methods to identify and validate repurposed drugs or drug combinations that may be effective against ADRD. This is a broad, multi-year funding announcement open from late 2024 through mid-2028.

What they want

Applicants must propose research using translational bioinformatics methods (e.g., computational analysis of large-scale genomic, proteomic, or pharmacological datasets) and/or experimental laboratory approaches to: (1) identify candidate drugs already approved or in development for other conditions that may be repositioned for Alzheimer's Disease and Related Dementias (ADRD); (2) develop and evaluate combination therapy strategies targeting ADRD pathways; and (3) validate findings through appropriate preclinical or translational experimental models. Clinical trials are not allowed under this announcement (PAR-25-374).

Technical requirements

Translational bioinformatics approaches required (e.g., computational analysis of genomic, proteomic, or pharmacological data)
Experimental laboratory validation approaches required
Clinical trials are explicitly not allowed
Must focus on Alzheimer's Disease and/or Related Dementias (ADRD)
Must address drug repositioning and/or combination therapy development

How they evaluate

Submission: Electronic submission via Grants.gov federal grants portal

Risks & flags

Extremely long open window (Dec 2024 – May 2028) suggests a rolling/standing announcement rather than a competitive single-award RFP — applicants should confirm submission due dates for specific review cycles
No dollar value disclosed — award size uncertainty makes cost planning difficult
Clinical trial exclusion is a hard constraint that may eliminate otherwise qualified investigators with trial-based approaches

Market context

inferred from NAICS

Professional, Scientific & Technical Services

NAICS 541714

US market size: $2.0T
Typical award: $25K – $50M

Typical buyers

All federal civilianDoDStates

Commonly required

8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

Translational Bioinformatics and Experimen…

Due May 07

Onboard ↗